K0706 CML Chronic Myeloid Leukemia
This drug can also be administered to people who are non-responsive or resistant to current drugs as imatinib, nilotinib, dasatinib and bosutinib. It is a potent inhibitor of Bcr-Abl and its mutant forms, including the T315I mutant.
CLINICAL TRIALS
Safety, Tolerability and Pharmacokinetic Study of K0706
April 27, 2017, ClinicalTrials.gov
Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706 in Healthy Subjects and in Subjects with Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
April 27, 2017, EU Clinical Trials Register
Safety, Tolerability and Pharmacokinetic Study of K0706
April 27, 2017, ClinicalTrials.gov
Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706 in Healthy Subjects and in Subjects with Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
April 27, 2017, EU Clinical Trials Register
ARTICLES
CLR_15_03 = Safety, Tolerability and Pharmacokinetics of K0706 [Asia, Europe, USA]
April 28, 2018, CML Advocate Network
A Two-Part Phase 1/2 Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706, a Novel Tyrosine Kinase Inhibitor (TKI), in Healthy Subjects and in Subjects with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
July 2017, MDAnderson Cancer center
CLR_15_03 = Safety, Tolerability and Pharmacokinetics of K0706 [Asia, Europe, USA]
April 28, 2018, CML Advocate Network
A Two-Part Phase 1/2 Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706, a Novel Tyrosine Kinase Inhibitor (TKI), in Healthy Subjects and in Subjects with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
July 2017, MDAnderson Cancer center
